8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study
Publication
, Conference
Prados, M; Cloughesy, T; Samant, MK; Fang, L; Das, A; Friedman, HS
Published in: European Journal of Cancer Supplements
September 2009
Duke Scholars
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
September 2009
Volume
7
Issue
2
Start / End Page
499 / 500
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Prados, M., Cloughesy, T., Samant, M. K., Fang, L., Das, A., & Friedman, H. S. (2009). 8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study. In European Journal of Cancer Supplements (Vol. 7, pp. 499–500). Elsevier BV. https://doi.org/10.1016/s1359-6349(09)71695-7
Prados, M., T. Cloughesy, M. K. Samant, L. Fang, A. Das, and H. S. Friedman. “8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study.” In European Journal of Cancer Supplements, 7:499–500. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71695-7.
Prados M, Cloughesy T, Samant MK, Fang L, Das A, Friedman HS. 8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study. In: European Journal of Cancer Supplements. Elsevier BV; 2009. p. 499–500.
Prados, M., et al. “8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study.” European Journal of Cancer Supplements, vol. 7, no. 2, Elsevier BV, 2009, pp. 499–500. Crossref, doi:10.1016/s1359-6349(09)71695-7.
Prados M, Cloughesy T, Samant MK, Fang L, Das A, Friedman HS. 8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study. European Journal of Cancer Supplements. Elsevier BV; 2009. p. 499–500.
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
September 2009
Volume
7
Issue
2
Start / End Page
499 / 500
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis